This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Edelman, M. J. Articles by Gandara, D. R. Search for Related Content PubMed PubMed Citation Articles by Edelman, M. J. Articles by Gandara, D. R.

Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)

Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel

¹ University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; ² Loyola University Stritch School of Medicine, Maywood, Illinois; ³ Southwest Oncology Group Statistical Center, Seattle, Washington; ⁴ Edward J. Hines Veterans Affairs Medical Center, Hines Illinois; ⁵ University of Texas Health Science Center, San Antonio, San Antonio, Texas; ⁶ Greenville Community Clinical Oncology Program, Greenville, South Carolina; ⁷ University of Colorado, Denver, Colorado; and ⁸ University of California, Davis Cancer Center, Sacramento, California

Purpose: Improving chemotherapeutic efficacy in non-small cell lung cancer (NSCLC) will require the development of new drugs or new strategies to better use currently available agents. Sequential administration offers an opportunity to increase drug diversity while maintaining dose intensity. On the basis of the data indicating the activity of taxanes as second-line therapy and the lack of efficacy for more than three cycles of platinum-based therapy, this randomized Phase II study tested the concept of planned sequential chemotherapy in advanced NSCLC.

Experimental Design: Patients with selected stage IIIb (pleural effusion)/stage IV NSCLC, performance status of 0–1 and normal organ function were eligible. Therapy: arm 1, carboplatin (area under the curve = 5.5 mg/ml x min day 1) and gemcitabine (1000 mg/m² days 1 and 8 every 21 days x 3) followed by paclitaxel (225 mg/m² every 21 days x 3) or arm 2, cisplatin (100 mg/m² day 1), vinorelbine (25 mg/m² days 1 and 8 every 21 d x 3) followed by docetaxel (75–100 mg/m² every 21 days x 3).

Results: Two-hundred four patients were accrued, of whom, 178 were eligible and evaluable. Eighty percent of patients were stage IV on arm 1 and 85% on arm 2. Response rates were 21 and 28% on arms 1 and 2, respectively. Median, 1-year and 2-year survivals were 9 months, 34 and 13%, and 9 months, 36 and 8%, on arms 1 and 2, respectively.

Conclusions: Sequential therapy, as used in this study, resulted in comparable efficacy to previous Southwest Oncology Group trials of two drug combinations in this population; however, it failed to meet criteria for further study.

This article has been cited by other articles:

				P. N. Lara Jr, M. W. Redman, K. Kelly, M. J. Edelman, S. K. Williamson, J. J. Crowley, and D. R. Gandara Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non-Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials J. Clin. Oncol., January 20, 2008; 26(3): 463 - 467. [Abstract] [Full Text] [PDF]

				J. Sculier, J. Lafitte, J Lecomte, C. Alexopoulos, O Van Cutsem, V Giner, A Efremidis, M. Berchier, T Collon, A. Meert, et al. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer Ann. Onc., June 1, 2007; 18(6): 1037 - 1042. [Abstract] [Full Text] [PDF]

				F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, and O. Belvedere Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature Oncologist, April 1, 2007; 12(4): 451 - 464. [Abstract] [Full Text] [PDF]

				H. Yasuda, M. Yamaya, K. Nakayama, T. Sasaki, S. Ebihara, A. Kanda, M. Asada, D. Inoue, T. Suzuki, T. Okazaki, et al. Randomized Phase II Trial Comparing Nitroglycerin Plus Vinorelbine and Cisplatin With Vinorelbine and Cisplatin Alone in Previously Untreated Stage IIIB/IV Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2006; 24(4): 688 - 694. [Abstract] [Full Text] [PDF]